Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Current Assets (2019 - 2025)

Historic Current Assets for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $111.2 million.

  • Pulmonx's Current Assets fell 2107.02% to $111.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.2 million, marking a year-over-year decrease of 2107.02%. This contributed to the annual value of $136.2 million for FY2024, which is 942.28% down from last year.
  • According to the latest figures from Q3 2025, Pulmonx's Current Assets is $111.2 million, which was down 2107.02% from $120.0 million recorded in Q2 2025.
  • In the past 5 years, Pulmonx's Current Assets registered a high of $239.3 million during Q1 2021, and its lowest value of $111.2 million during Q3 2025.
  • Moreover, its 5-year median value for Current Assets was $164.4 million (2023), whereas its average is $169.7 million.
  • As far as peak fluctuations go, Pulmonx's Current Assets surged by 30926.97% in 2021, and later plummeted by 2107.02% in 2025.
  • Pulmonx's Current Assets (Quarter) stood at $208.0 million in 2021, then dropped by 18.77% to $169.0 million in 2022, then dropped by 10.97% to $150.4 million in 2023, then dropped by 9.42% to $136.2 million in 2024, then fell by 18.36% to $111.2 million in 2025.
  • Its Current Assets was $111.2 million in Q3 2025, compared to $120.0 million in Q2 2025 and $123.9 million in Q1 2025.